We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
GLP‐1 receptor agonists for hidradenitis suppurativa: Navigating benefits, risks, and ethical considerations.
- Authors
Gu, Yaron; Sebaratnam, Deshan F.
- Abstract
This article discusses the potential use of GLP-1 receptor agonists (GLP-1 RAs) for the treatment of hidradenitis suppurativa (HS), a skin condition associated with obesity and cardiovascular disease risk factors. GLP-1 RAs have been trialed in psoriasis patients with metabolic derangements and have shown promising results in reducing psoriasis severity. However, the evidence supporting the use of GLP-1 RAs in HS patients is limited to a singular case report. The article also raises ethical considerations, such as the potential impact of off-label usage of GLP-1 RAs on the supply for patients with type 2 diabetes. Overall, while the therapeutic potential of GLP-1 RAs in HS is worth considering, the unknown risk-benefit and ethical concerns should be taken into account.
- Subjects
HIDRADENITIS suppurativa; GLUCAGON-like peptide-1 agonists; GLUCAGON-like peptide-1 receptor; GASTROPARESIS
- Publication
International Journal of Dermatology, 2024, Vol 63, Issue 5, pe100
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.17108